Neurotrophic keratopathy and Wallenberg – Zakharchenko syndrome: a clinical case

Abstract

BACKGROUND: Degenerative changes of cornea after transection of the trigeminal nerve were first described by F. Magendie in 1824. Neurotrophic keratopathy is considered to be an orphan disease which lately has been recognized more and more often. According to literature data, neurotropchic keratopathy affects 5 individuals in 10,000. The diagnosis is difficult due to the lack of information about this condition, the rare occurrence and the presence of a large number of etiological factors.

AIM: To determine the causes of the neurotrophic keratopathy development and the treatment tactics in a patient with a neurological disease. The article presents a case of neurotrophic keratopathy in a patient with Wallenberg – Zakharchenko syndrome.

Because of the fact that neurotrophic keratopathy was diagnosed late and the correct treatment did not start in time, further progression of the pathological process in the cornea could not be avoided. Periodic recurrence of neurotrophic keratopathy is associated with an underlying chronic neurological disease.

CONCLUSIONS: Neurotrophic keratopathy requires early diagnosis. In certain clinical cases, for the successful treatment of this pathology, it is necessary to prescribe systemic therapy.

Keywords

cornea / neurotrophic keratopathy / neurotrophic keratitis / Wallenberg – Zakharchenko syndrome / corneal erosion / recurrent corneal erosion / persistent epithelial defect / in vivo confocal microscopy

References

[1] Magendie F. The influence of the fifth pair of nerves on nutrition and function of the eye. J Physiol Exp Pathol. 1824;4:176–182. (In French.)

[2] Magendie F. De l’influence de la cinquieme paire de nerfs sur la nutrition et les fonctions de l’oeil // J Physiol Exp Pathol. 1824. Vol. 4. P. 176–182. (In French)

[3] Dua HS, Said DG, Messmer EM, et al. Neuropathic Keratopathy. [Internet] Progress in Retinal and Eye Research, 2018. Available from: https://research.birmingham.ac.uk/portal/en/publications/neurotrophic-keratopathy(2478a374-6546-4972-a335-54590310c27c).html. DOI: 10.1016/j.preteyeres.2018.04.003

[4] Dua H.S., Said D.G., Messmer E.M., et al. Neuropathic Keratopathy. [Internet] Progress in Retinal and Eye Research, 2018. Доступ по ссылке: https://research.birmingham.ac.uk/portal/en/publications/neurotrophic-keratopathy(2478a374-6546-4972-a335-54590310c27c).html.DOI: 10.1016/j.preteyeres.2018.04.003

[5] Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003;17:989–995. DOI: 10.1038/sj.eye.6700616

[6] Bonini S., Rama P., Olzi D., Lambiase A. Neurotrophic keratitis // Eye (Lond). 2003. Vol. 17. P. 989–995. DOI: 10.1038/sj.eye.6700616

[7] Morishige N, Morita Y, Yamada N, et al. Congenital hypoplastic trigeminal nerve revealed by manifestation of corneal disorders likely caused by neural factor deficiency. Case reports in ophthalmology. 2014;5(2):181–185. DOI: 10.1159/000364899

[8] Morishige N., Morita Y., Yamada N., et al. Congenital hypoplastic trigeminal nerve revealed by manifestation of corneal disorders likely caused by neural factor deficiency // Case reports in ophthalmology. 2014. Vol. 5. No. 2. P. 181–185. DOI: 10.1159/000364899

[9] Lin X, Xu B, Sun Y, et al. Comparison of deep anterior lamellar keratoplasty and penetrating keratoplasty with respect to postoperative corneal sensitivity and tear film function. Graefe’s archive for clinical and experimental ophthalmology. 2014;252:1779–1787. DOI: 10.1007/s00417-014-2748-6

[10] Lin X., Xu B., Sun Y., et al. Comparison of deep anterior lamellar keratoplasty and penetrating keratoplasty with respect to postoperative corneal sensitivity and tear film function // Graefe’s archive for clinical and experimental ophthalmology. 2014. Vol. 252. P. 1779–1787. DOI: 10.1007/s00417-014-2748-6

[11] Wilson SE, Ambrosio R. Laser in situ keratomileusis-induced neurotrophic epitheliopathy. Am J Ophthalmol. 2001;132(3):405–406. DOI: 10.1016/s0002-9394(01)00995-3

[12] Wilson S.E., Ambrosio R. Laser in situ keratomileusis-induced neurotrophic epitheliopathy // Am J Ophthalmol. 2001. Vol. 132. No. 3. P. 405–406. DOI: 10.1016/s0002-9394(01)00995-3

[13] Wilson SE, Ambrosio R. Laser in situ keratomileusis-induced neurotrophic epitheliopathy. Am J Ophthalmol. 2001;132(3):405–406. DOI: 10.1016/s0002-9394(01)00995-3

[14] Wasilewski D., Mello G.H., Moreira H. Impact of collagen crosslinking on corneal sensitivity in keratoconus patients // Cornea. 2013. Vol. 32. No. 7. P. 899–902. DOI: 10.1097/ICO.0b013e31827978c8

[15] Lockwood A, Hope-Ross M, Chell P. Neurotrophic keratopathy and diabetes mellitus. Eye (Lond). 2006;20:837–839. DOI: 10.1038/sj.eye.6702053

[16] Lockwood A., Hope-Ross M., Chell P. Neurotrophic keratopathy and diabetes mellitus // Eye (Lond). 2006. Vol. 20. P. 837–839. DOI: 10.1038/sj.eye.6702053

[17] Semeraro F, Forbice E, Romano V, et al. Neurotrophic keratitis. Ophthalmologica. 2014;231:191–197. DOI: 10.1159/000354380

[18] Semeraro F., Forbice E., Romano V., et al. Neurotrophic keratitis // Ophthalmologica. 2014. Vol. 231. P. 191–197. DOI: 10.1159/000354380

[19] Hsu HY, Modi D. Etiologies, Quantitative Hypoesthesia, and Clinical Outcomes of Neurotrophic Keratopathy. Eye Contact Lens. 2015;41(5):314–317. DOI: 10.1097/ICL.0000000000000133

[20] Hsu H.Y., Modi D. Etiologies, Quantitative Hypoesthesia, and Clinical Outcomes of Neurotrophic Keratopathy // Eye Contact Lens. 2015. Vol. 41. No. 5. P. 314–317. DOI: 10.1097/ICL.0000000000000133

[21] Mackie IA. Neuroparalytic keratitis. In: Fraunfelder FT, Roy FH, Grove J, editors. Current Ocular Therapy, 4 ed. WB Saunders. Philadelphia, 1995. P. 452–454.

[22] Mackie I.A. Neuroparalytic keratitis. In: F.T.Fraunfelder, F.H. Roy, J. Grove, editors. Current Ocular Therapy, 4 ed. W.B. Saunders. Philadelphia, 1995. P. 452–454.

[23] Riks IA, Papanyan SS, Astakhov SYu, Novikov SA. Novel clinico-morphological classification of the corneal endothelial-epithelial dystrophy. Ophthalmology journal. 2017;10(3):46–52. (In Russ.) DOI: 10.17816/OV10346-52

[24] Рикс И.А., Папанян С.С., Астахов С.Ю., Новиков С.А. Новая клинико-морфологическая классификация эндотелиально-эпителиальной дистрофии роговицы // Офтальмологические ведомости. 2017. Т. 10, № 3. С. 46–52. DOI: 10.17816/OV10346-52

[25] Astakhov SYu, Novikov SA, Papanyan SS, Riks IA. Еvaluate the Effectiveness of Accelerated Collagen Crosslinking in the Treatment of Corneal Endothelial Decompensation. Ophthalmology in Russia. 2020;17(4): 699–704. (In Russ.) DOI: 10.18008/1816-5095-2020-4-699-704

[26] Астахов С.Ю., Новиков С.А., Папанян С.С., Рикс И.А. Оценка эффективности ускоренного коллагенового кросслинкинга в лечении эндотелиальной декомпенсации роговицы // Офтальмология. 2020. Т. 17, № 4. С. 699–704. DOI: 10.18008/1816-5095-2020-4-699-704

[27] Mastropasqua L, Nubile M, Lanzini M, et al. In vivo microscopic and optical coherence tomography classification of neurotrophic keratopathy. J Cell Physiol. 2019;234(5):6108–6115. DOI: 10.1002/jcp.27345

[28] Mastropasqua L., Nubile M., Lanzini M., et al. In vivo microscopic and optical coherence tomography classification of neurotrophic keratopathy // J Cell Physiol. 2019. Vol. 234. No. 5. P. 6108–6115. DOI: 10.1002/jcp.27345

[29] Kugadas A, Gadjeva M. Impact of Microbiome on Ocular Health. Ocul Surf. 2016;14(3):342–349. DOI: 10.1016/j.jtos.2016.04.004

[30] Kugadas A., Gadjeva M. Impact of Microbiome on Ocular Health // Ocul Surf. 2016. Vol. 14. No. 3. P. 342–349. DOI: 10.1016/j.jtos.2016.04.004

[31] Ayaki M, Iwasawa A, Niwano Y. In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines. Biocontrol Sci. 2012;17(2):93–99. DOI: 10.4265/bio.17.93

[32] Ayaki M., Iwasawa A., Niwano Y. In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines // Biocontrol Sci. 2012. Vol. 17. No. 2. P. 93–99. DOI: 10.4265/bio.17.93

[33] Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000;107(7):1347–1351. DOI: 10.1016/s0161-6420(00)00163-9

[34] Bonini S., Lambiase A., Rama P., et al. Topical treatment with nerve growth factor for neurotrophic keratitis // Ophthalmology. 2000. Vol. 107. No. 7. P. 1347–1351. DOI: 10.1016/s0161-6420(00)00163-9

[35] Yamada N, Matsuda R, Morishige N, et al. Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol. 2008;92(7):896–900. DOI: 10.1136/bjo.2007.130013

[36] Yamada N., Matsuda R., Morishige N., et al. Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy // Br J Ophthalmol. 2008. Vol. 92. No. 7. P. 896–900. DOI: 10.1136/bjo.2007.130013

[37] Guerra M, Marques S, Gil JQ, et al. Neurotrophic Keratopathy: Therapeutic Approach Using a Novel Matrix Regenerating Agent. J Ocul Pharmacol Ther. 2017;33(9):662–669. DOI: 10.1089/jop.2017.0010

[38] Guerra M., Marques S., Gil J.Q., et al. Neurotrophic Keratopathy: Therapeutic Approach Using a Novel Matrix Regenerating Agent // J Ocul Pharmacol Ther. 2017. Vol. 33. No. 9. P. 662–669. DOI: 10.1089/jop.2017.0010

[39] Trufanov SV. Cyanoacrylate adhesive in surgical treatment of corneal perforation (clinical case). The Russian annals of ophthalmology. 2020;136(5–2):232–236. (In Russ.) DOI: 10.17116/oftalma2020136052232

[40] Труфанов С.В. Применение цианоакрилатного клея в хирургическом лечении перфорации роговицы (клиническое наблюдение) // Вестник офтальмологии. 2020. Т. 136, № 5–2. С. 232–236. DOI: 10.17116/oftalma2020136052232

RIGHTS & PERMISSIONS

Ezugbaya M.B., Astakhov S.Y., Riks I.A., Papanyan S.S., Boutaba R., Mikhalchenko Y.G., Yakushenko A.R.